Trial reportCell transplantation2018
Significant Improvement of Acute Complete Spinal Cord Injury Patients Diagnosed by a Combined Criteria Implanted with NeuroRegen Scaffolds and Mesenchymal Stem Cells.
Trial report in Cell transplantation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
84 citing papers in PubMed, 7 syntheses or guidelines pooled it, 164 citations in OpenAlex.
- Pooled it
- Biomaterial-mediated delivery of traditional Chinese medicine ingredients for spinal cord injury: a systematic review.Frontiers in pharmacology · 2024Pooled it
- Bibliometric analysis of nanotechnology in spinal cord injury: current status and emerging frontiers.Frontiers in pharmacology · 2024Pooled it
- Mesenchymal Stem Cell Therapy in Traumatic Spinal Cord Injury: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Systematic Evaluation of Spinal Cord Injury Animal Models in the Field of Biomaterials.Tissue engineering. Part B, Reviews · 2022Pooled it
- Are Cell-Based Therapies Safe and Effective in the Treatment of Neurodegenerative Diseases? A Systematic Review with Meta-Analysis.Biomolecules · 2022Pooled it
- Comparing the Efficacy and Safety of Cell Transplantation for Spinal Cord Injury: A Systematic Review and Bayesian Network Meta-Analysis.Frontiers in cellular neuroscience · 2022Pooled it
- Repairing spinal cord injuries: The most promising polymeric biomaterials and local drug delivery.Neural regeneration research · 2026Article
- Clinical trial landscape of cell therapy for spinal cord injury: from integrated practices to future developments.BMC medicine · 2026Article
- Restoring neuroplasticity after CNS trauma: cell therapy approaches in spinal cord and traumatic brain injury.Journal of translational medicine · 2026Review
- Mechanisms and Applications of Conductive Biomaterials in Spinal Cord Injury Repair.Biomaterials research · 2026Review
- Biomaterial-Based Emergency Intervention for Secondary Spinal Cord Injury.Small science · 2025Review
- Poly-L-Ornithine coated plant scaffolds support motor recovery in rats after traumatic spinal cord injury.Scientific reports · 2025Article
- An overview of stem cells and cell products involved in trauma injury.Regenerative therapy · 2025Review
- Traumatic Spinal Cord Injury: Review of the Literature.Journal of clinical medicine · 2025Review
- Stem cell therapies in the clinic.Bioengineering & translational medicine · 2025Review
- Revisiting the Emerging Role of Light-Based Therapies in the Management of Spinal Cord Injuries.Molecular neurobiology · 2025Review
- Review
- Exosome-Loaded Bioscaffolds for Spinal Cord Injuries: A Review.Stem cells international · 2025Review
- Preclinical evaluation of aligned fibrin nanofibre hydrogels in a non-human primate model of spinal cord injury: A pilot study.Biomaterials translational · 2025Article
24 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stem cells and biomaterials transplantation hold a promising treatment for functional recovery in spinal cord injury (SCI) animal models. However, the functional recovery of complete SCI patients was still a huge challenge in clinic. Additionally, there is no clinical standard procedure available to diagnose precisely an acute patient as complete SCI. Here, two acute SCI patients, with injury at thoracic 11 (T11) and cervical 4 (C4) level respectively, were judged as complete injury by a stricter method combined with American Spinal Injury Association (ASIA) Impairment Scale, magnetic resonance imaging (MRI) and nerve electrophysiology. Collagen scaffolds, named NeuroRegen scaffolds, with human umbilical cord mesenchymal stem cells (MSCs) were transplanted into the injury site. During 1 year follow up, no obvious adverse symptoms related to the functional scaffolds implantation were found after treatment. The recovery of the sensory and motor functions was observed in the two patients. The sensory level expanded below the injury level, and the patients regained the sense function in bowel and bladder. The thoracic SCI patient could walk voluntary with the hip under the help of brace. The cervical SCI patient could raise his lower legs against the gravity in the wheelchair and shake his toes under control. The injury status of the two patients was improved from ASIA A complete injury to ASIA C incomplete injury. Furthermore, the improvement of sensory and motor functions was accompanied with the recovery of the interrupted neural conduction. These results showed that the supraspinal control of movements below the injury was regained by functional scaffolds implantation in the two patients who were judged as the complete injury with combined criteria, it suggested that functional scaffolds transplantation could serve as an effective treatment for acute complete SCI patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.